RecallRadar

FDA Drug recall D-0620-2025

4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10 mL (0.5 mEq/mL), For Intravenous Use Only, 10 mL Single Dose Vial, Rx Only, Manufactured a…

On 2025-09-17 the FDA classified a Class II recall of 4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10 mL (0.5 mEq/mL), For Intravenous Use Only, 10 mL Single Dose Vial, Rx Only, Manufactured a… by Exela Pharma Sciences, citing failed Impurities/Degradation Specifications: out of specification results for arsenic in the impurities tested.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0620-2025
ClassificationClass II
Statusongoing
Initiated2025-07-30
Published2025-09-17
Last updated2026-09-13 11:52 UTC
CompanyExela Pharma Sciences
DistributionUS

Product

4.2% Sodium Bicarbonate Injection, USP, 5 mEq/10 mL (0.5 mEq/mL), For Intravenous Use Only, 10 mL Single Dose Vial, Rx Only, Manufactured and Distributed by: Exela Pharma Sciences, LLC, Lenoir, NC 28645 USA, NDC 51754-5012-1 (vial); 51754-5012-4 (carton)

Reason

Failed Impurities/Degradation Specifications: out of specification results for arsenic in the impurities tested.

Identifiers

ndc51754-5001-5
ndc51754-5001-4
ndc51754-5011-4
ndc51754-5002-5
ndc51754-5012-4
ndc51754-5012-1
code_infoLot # 10004077, Exp. 02/28/2026

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: ongoing.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0620-2025%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.